BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herbener VJ, Burster T, Goreth A, Pruss M, von Bandemer H, Baisch T, Fitzel R, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA, Strobel H. Considering the Experimental use of Temozolomide in Glioblastoma Research. Biomedicines 2020;8:E151. [PMID: 32512726 DOI: 10.3390/biomedicines8060151] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Waghule T, Laxmi Swetha K, Roy A, Narayan Saha R, Singhvi G. Exploring temozolomide encapsulated PEGylated Liposomes and Lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. Eur J Pharm Biopharm 2023:S0939-6411(23)00064-4. [PMID: 36924995 DOI: 10.1016/j.ejpb.2023.03.004] [Reference Citation Analysis]
2 Lombardi F, Augello FR, Artone S, Ayroldi E, Giusti I, Dolo V, Cifone MG, Cinque B, Palumbo P. Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype. Front Oncol 2022;12:933746. [DOI: 10.3389/fonc.2022.933746] [Reference Citation Analysis]
3 Liu J, Zhu X, Gao L, Geng R, Tao X, Xu H, Chen Z. Expression and Prognostic Role of Glia Maturation Factor-γ in Gliomas. Front Mol Neurosci 2022;15:906762. [DOI: 10.3389/fnmol.2022.906762] [Reference Citation Analysis]
4 Persano F, Gigli G, Leporatti S. Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas. IJMS 2022;23:3360. [DOI: 10.3390/ijms23063360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
5 Xu P, Westhoff MA, Hadzalic A, Debatin KM, Winiarski L, Oleksyszyn J, Wirtz CR, Knippschild U, Burster T. Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma. ACS Omega 2022;7:5929-36. [PMID: 35224353 DOI: 10.1021/acsomega.1c06169] [Reference Citation Analysis]
6 Lombardi F, Augello FR, Artone S, Gugu MK, Cifone MG, Cinque B, Palumbo P. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Int J Mol Sci 2022;23:1545. [PMID: 35163465 DOI: 10.3390/ijms23031545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Burster T, Traut R, Yermekkyzy Z, Mayer K, Westhoff MA, Bischof J, Knippschild U. Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Front Cell Dev Biol 2021;9:695325. [PMID: 34485282 DOI: 10.3389/fcell.2021.695325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
8 Soni V, Adhikari M, Simonyan H, Lin L, Sherman JH, Young CN, Keidar M. In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma. Cancers (Basel) 2021;13:4485. [PMID: 34503293 DOI: 10.3390/cancers13174485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Tsidulko AY, Shevelev OB, Khotskina AS, Kolpakova MA, Suhovskih AV, Kazanskaya GM, Volkov AM, Aidagulova SV, Zavyalov EL, Grigorieva EV. Chemotherapy-Induced Degradation of Glycosylated Components of the Brain Extracellular Matrix Promotes Glioblastoma Relapse Development in an Animal Model. Front Oncol 2021;11:713139. [PMID: 34350124 DOI: 10.3389/fonc.2021.713139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sun X, Turcan S. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells 2021;10:1225. [PMID: 34067729 DOI: 10.3390/cells10051225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
11 Lah Turnšek T, Jiao X, Novak M, Jammula S, Cicero G, Ashton AW, Joyce D, Pestell RG. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. Int J Mol Sci 2021;22:4464. [PMID: 33923334 DOI: 10.3390/ijms22094464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Dias AF, Scholl JN, Moritz CEJ, Kagami LP, das Neves GM, Eifler-Lima VL, Cruz-López O, Conejo-García A, Sévigny J, Battastini AMO, Campos JM, Figueiró F. New insights into cytotoxic mechanisms of bozepinib against glioblastoma. Eur J Pharm Sci 2021;162:105823. [PMID: 33781855 DOI: 10.1016/j.ejps.2021.105823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Burster T, Gärtner F, Bulach C, Zhanapiya A, Gihring A, Knippschild U. Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells. Pharmaceuticals (Basel) 2021;14:236. [PMID: 33800301 DOI: 10.3390/ph14030236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Lah TT, Novak M, Pena Almidon MA, Marinelli O, Žvar Baškovič B, Majc B, Mlinar M, Bošnjak R, Breznik B, Zomer R, Nabissi M. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells 2021;10:340. [PMID: 33562819 DOI: 10.3390/cells10020340] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]